Showing 1,701 - 1,720 results of 13,350 for search '(( significant increase decrease ) OR ( significantly ((altered decrease) OR (teer decrease)) ))*', query time: 0.66s Refine Results
  1. 1701
  2. 1702
  3. 1703

    Supplementary Material 4–DMSO does not alter zebrafish motility at concentrations below 1%. by Geyse Gomes (22075629)

    Published 2025
    “…Eight independent experiments were performed with control, 0.1% DMSO, 0.3% DMSO, 0.5% DMSO, 1% DMSO and 2% DMSO. No significant alterations in embryos motility were observed, although a dose-dependent tendency of decrease in locomotion was observed. …”
  4. 1704
  5. 1705
  6. 1706
  7. 1707
  8. 1708
  9. 1709
  10. 1710
  11. 1711
  12. 1712
  13. 1713
  14. 1714
  15. 1715

    Supplementary file 2_Gut microbiome and serum metabolome alterations in osteosarcoma patients.xlsx by Chao Li (145513)

    Published 2025
    “…Principal component analysis identified 33 microbial species that exhibited significant changes in osteosarcoma patients. Of note, the relative abundance of Alloprevotella and Prevotella increased in these patients. …”
  16. 1716

    Supplementary file 1_Gut microbiome and serum metabolome alterations in osteosarcoma patients.docx by Chao Li (145513)

    Published 2025
    “…Principal component analysis identified 33 microbial species that exhibited significant changes in osteosarcoma patients. Of note, the relative abundance of Alloprevotella and Prevotella increased in these patients. …”
  17. 1717

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  18. 1718

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  19. 1719

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  20. 1720

    Data Sheet 1_The gastric microbiome altered by A4GNT deficiency in mice.zip by Dawei Gong (3070773)

    Published 2025
    “…</p>Results<p>In A4gnt<sup>−/−</sup> mice, which spontaneously develop gastric cancer, the community structure of the gastric microbiome was altered. The relative abundance of mutagenic Desulfovibrio and proinflammatory Prevotellamassilia in these mice was significantly increased, especially 4 weeks after birth. …”